

Igor N Bondarenko

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5779919/publications.pdf>

Version: 2024-02-01

177
papers

39,555
citations

17440

63
h-index

5988

160
g-index

177
all docs

177
docs citations

177
times ranked

34150
citing authors

#	ARTICLE	IF	CITATIONS
1	Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2011, 364, 2517-2526.	27.0	4,074
2	Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 113-125.	27.0	3,530
3	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <i>Lancet</i> , The, 2019, 393, 1819-1830.	13.7	2,347
4	Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1116-1127.	27.0	2,319
5	Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. <i>New England Journal of Medicine</i> , 2020, 382, 41-50.	27.0	1,725
6	The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. <i>Lancet Oncology</i> , The, 2015, 16, 25-35.	10.7	1,574
7	Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 1877-1888.	27.0	1,572
8	Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 663-671.	1.6	1,524
9	Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet Oncology</i> , The, 2016, 17, 425-439.	10.7	1,344
10	Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. <i>Lancet</i> , The, 2019, 394, 1929-1939.	13.7	1,274
11	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet</i> , The, 2015, 386, 444-451.	13.7	1,175
12	RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative, Locally Recurrent or Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 1252-1260.	1.6	932
13	Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2046-2054.	1.6	931
14	Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 626-636.	27.0	909
15	Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. <i>Lancet Oncology</i> , The, 2014, 15, 143-155.	10.7	823
16	Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 1926-1936.	27.0	805
17	Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. <i>Annals of Oncology</i> , 2011, 22, 1535-1546.	1.2	696
18	Weekly Nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Final Results of a Phase III Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2055-2062.	1.6	676

#	ARTICLE	IF	CITATIONS
19	Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. <i>Annals of Oncology</i> , 2013, 24, 75-83.	1.2	567
20	Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4594-4600.	1.6	553
21	Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. <i>Annals of Oncology</i> , 2017, 28, 1631-1639.	1.2	549
22	Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. <i>Annals of Oncology</i> , 2010, 21, 1712-1717.	1.2	468
23	Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1191-1196.	1.6	445
24	Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. <i>Lancet</i> , The, 2021, 397, 592-604.	13.7	441
25	Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. <i>Lancet</i> , The, 2016, 388, 2997-3005.	13.7	435
26	Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 3791-3799.	1.6	388
27	Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 51-65.	10.7	356
28	Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1467-1482.	10.7	265
29	Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 195-202.	1.6	252
30	First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 921-929.	1.6	244
31	Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 1557.	7.1	242
32	Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt337-djt337.	6.3	218
33	Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1269-1282.	10.7	207
34	A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. <i>Annals of Oncology</i> , 2014, 25, 1328-1333.	1.2	202
35	Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. <i>Lancet Oncology</i> , The, 2011, 12, 795-805.	10.7	199
36	Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III). <i>Journal of Clinical Oncology</i> , 2012, 30, 3588-3595.	1.6	194

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. <i>Annals of Oncology</i> , 2014, 25, 1340-1346.	1.2	187
38	Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 510-520.	10.7	183
39	Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. <i>Annals of Oncology</i> , 2018, 29, 154-161.	1.2	161
40	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. <i>Lancet</i> , The, 2017, 390, 2266-2277.	13.7	153
41	Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity. <i>Journal of Clinical Oncology</i> , 2013, 31, 4453-4461.	1.6	147
42	Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) $\geq 1\%$: Open-label, phase 3 KEYNOTE-042 study.. <i>Journal of Clinical Oncology</i> , 2018, 36, LBA4-LBA4.	1.6	146
43	Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. <i>Breast Cancer Research</i> , 2016, 18, 67.	5.0	140
44	MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 916-929.	10.7	131
45	Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2) \geq Positive Metastatic Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 37.	7.4	129
46	Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 4248-4254.	7.0	129
47	Randomized Phase III Trial Comparing Single-Agent Paclitaxel Poliglumex (CT-2103, PPX) with Single-Agent Gemcitabine or Vinorelbine for the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2008, 3, 728-734.	1.1	126
48	Fluorouracil, Leucovorin, and Irinotecan Plus Either Sunitinib or Placebo in Metastatic Colorectal Cancer: A Randomized, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1341-1347.	1.6	122
49	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. <i>Annals of Oncology</i> , 2016, 27, 417-423.	1.2	122
50	A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC). <i>Annals of Oncology</i> , 2014, 25, 824-831.	1.2	112
51	Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDIAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. <i>European Journal of Cancer</i> , 2017, 70, 146-155.	2.8	108
52	Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 4522-4529.	1.6	97
53	Anomalous Aortic Origin of a Coronary Artery. <i>World Journal for Pediatric & Congenital Heart Surgery</i> , 2014, 5, 22-30.	0.8	91
54	A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). <i>Annals of Oncology</i> , 2015, 26, 1741-1748.	1.2	87

#	ARTICLE	IF	CITATIONS
55	Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GE) cancer: RILOMET-1 study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4000-4000.	1.6	85
56	Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 678-689.	10.7	83
57	Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. <i>Annals of Oncology</i> , 2012, 23, 610-617.	1.2	82
58	A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)â€“only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer. <i>Gynecologic Oncology</i> , 2017, 146, 484-490.	1.4	81
59	Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2â€“Positive Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 968-974.	1.6	78
60	Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). <i>Annals of Oncology</i> , 2019, 30, 766-773.	1.2	78
61	Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy. <i>BMC Cancer</i> , 2013, 13, 386.	2.6	75
62	Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer. <i>British Journal of Cancer</i> , 2013, 108, 1985-1993.	6.4	74
63	Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2â€“ advanced breast cancer (PALOMA-1, TRIO-18). <i>Breast Cancer Research and Treatment</i> , 2020, 183, 419-428.	2.5	73
64	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. <i>European Journal of Cancer</i> , 2015, 51, 833-840.	2.8	71
65	Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2â€“ ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study. <i>Clinical Cancer Research</i> , 2022, 28, 3433-3442.	7.0	65
66	Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptorâ€“Positive Locally Advanced or Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 6822-6830.	7.0	63
67	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 105-120.	10.7	61
68	Repair of Anomalous Aortic Origin of a Coronary Artery in 113 Patients. <i>World Journal for Pediatric & Congenital Heart Surgery</i> , 2014, 5, 507-514.	0.8	60
69	Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 2015, 51, 317-326.	2.8	58
70	Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer. <i>Annals of Oncology</i> , 2016, 27, 106-113.	1.2	58
71	A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results. <i>European Journal of Cancer</i> , 2018, 93, 19-27.	2.8	58
72	Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer. <i>Annals of Oncology</i> , 2015, 26, 497-504.	1.2	56

#	ARTICLE	IF	CITATIONS
73	Untreated metastatic diffuse gastric adenocarcinoma (DGAC): Randomized phase III study of S-1 and cisplatin vs. 5-FU and cisplatin (the DIGEST trial).. Journal of Clinical Oncology, 2015, 33, 4015-4015.	1.6	56
74	Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18).. Journal of Clinical Oncology, 2017, 35, 1001-1001.	1.6	55
75	A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy. Journal of Clinical Oncology, 2016, 34, 1197-1207.	1.6	52
76	A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors. Current Medical Research and Opinion, 2010, 26, 2339-2346.	1.9	51
77	Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. British Journal of Haematology, 2018, 182, 583-586.	2.5	49
78	Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study. Investigational New Drugs, 2013, 31, 1283-1293.	2.6	48
79	Long-term functional health status and exercise test variables for patients with pulmonary atresia with intact ventricular septum: A Congenital Heart Surgeons Society study. Journal of Thoracic and Cardiovascular Surgery, 2013, 145, 1018-1027.e3.	0.8	47
80	Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer. BMC Cancer, 2014, 14, 290.	2.6	46
81	Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled Phase III trial. International Journal of Cancer, 2021, 148, 2557-2570.	5.1	44
82	PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study. British Journal of Cancer, 2019, 120, 172-182.	6.4	43
83	A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma. Annals of Oncology, 2016, 27, 680-687.	1.2	40
84	Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial.. Journal of Clinical Oncology, 2012, 30, 4501-4501.	1.6	40
85	Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer. European Journal of Cancer, 2019, 120, 1-9.	2.8	39
86	NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron. Supportive Care in Cancer, 2017, 25, 1127-1135.	2.2	37
87	PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study. BioDrugs, 2019, 33, 555-570.	4.6	36
88	Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 845-855.	8.1	32
89	A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results. British Journal of Cancer, 2015, 113, 1140-1147.	6.4	30
90	Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study. Targeted Oncology, 2017, 12, 475-485.	3.6	30

#	ARTICLE	IF	CITATIONS
91	A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer. <i>Annals of Oncology</i> , 2017, 28, 2142-2148.	1.2	30
92	Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer. <i>Annals of Oncology</i> , 2018, 29, 1548-1553.	1.2	30
93	Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel. <i>Lung Cancer</i> , 2015, 90, 267-273.	2.0	26
94	Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer. <i>Acta Oncologica</i> , 2017, 56, 441-447.	1.8	26
95	Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation-positive melanoma receiving adjuvant vemurafenib. <i>Annals of Oncology</i> , 2020, 31, 153-159.	1.2	25
96	ZoptEC: Phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer (NCT01767155).. <i>Journal of Clinical Oncology</i> , 2018, 36, 5503-5503.	1.6	25
97	A Randomized Phase II/III Study of Naptumomab Estafenatox + IFN γ versus IFN γ in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis. <i>Clinical Cancer Research</i> , 2016, 22, 3172-3181.	7.0	22
98	Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, e204429.	7.1	22
99	Phase III, Double-Blind, Controlled Trial of Atamestane Plus Toremifene Compared With Letrozole in Postmenopausal Women With Advanced Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 4961-4966.	1.6	21
100	Efficacy and Safety of Balugrastim Compared With Pegfilgrastim in Patients With Breast Cancer Receiving Chemotherapy. <i>Clinical Breast Cancer</i> , 2014, 14, 101-108.	2.4	21
101	A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel. <i>Oncologist</i> , 2016, 21, 7-15.	3.7	21
102	A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 146, 12-18.	2.0	21
103	Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial. <i>BioDrugs</i> , 2021, 35, 337-350.	4.6	21
104	Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 6002-6009.	7.0	20
105	Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies. <i>Supportive Care in Cancer</i> , 2016, 24, 267-273.	2.2	18
106	Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy. <i>SpringerPlus</i> , 2015, 4, 316.	1.2	17
107	Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 149-155.	2.5	16
108	A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, 531-540.	2.6	15

#	ARTICLE	IF	CITATIONS
109	Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer. <i>BMC Cancer</i> , 2015, 15, 339.	2.6	14
110	Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane. <i>Annals of Oncology</i> , 2018, 29, 1195-1202.	1.2	13
111	Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC). <i>BioDrugs</i> , 2021, 35, 417-428.	4.6	13
112	Zolbetuximab combined with EOX as first-line therapy in advanced CLDN18.2+ gastric (G) and gastroesophageal junction (GEJ) adenocarcinoma: Updated results from the FAST trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 16-16.	1.6	13
113	An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2015, 16, 92-99.	2.6	12
114	A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1).. <i>Journal of Clinical Oncology</i> , 2013, 31, CRA8007-CRA8007.	1.6	12
115	Phase II dose-finding study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy. <i>Medical Oncology</i> , 2015, 32, 623.	2.5	11
116	A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 509-509.	1.6	11
117	Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 543-543.	1.6	11
118	Late Survival and Patient-Perceived Health Status of the Congenital Heart Surgeons Society dextro-Transposition of the Great Arteries Cohort. <i>Annals of Thoracic Surgery</i> , 2019, 108, 1447-1455.	1.3	9
119	Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-14010 versus Herceptin.. <i>Journal of Clinical Oncology</i> , 2016, 34, LBA503-LBA503.	1.6	9
120	Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger patients. <i>Supportive Care in Cancer</i> , 2016, 24, 4913-4920.	2.2	8
121	Significant Improvements in Mortality After the Fontan Operation in Children With Down Syndrome. <i>Annals of Thoracic Surgery</i> , 2020, 109, 835-841.	1.3	8
122	Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 327-327.	1.6	8
123	Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600E mutant unresectable or metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9507-9507.	1.6	8
124	363...KEYNOTE-042 5-year survival update: pembrolizumab versus chemotherapy in patients with previously untreated, PD-L1 positive, locally advanced or metastatic non-small-cell lung cancer. , 2021, 9, A390-A390.		8
125	A randomized phase 2 study of abemaciclib versus docetaxel in patients with stage IV squamous non-small cell lung cancer (sqNSCLC) previously treated with platinum-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9059-9059.	1.6	7
126	Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study. <i>BioDrugs</i> , 2022, 36, 55-69.	4.6	7

#	ARTICLE	IF	CITATIONS
127	Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy. <i>BMC Cancer</i> , 2019, 19, 122.	2.6	6
128	Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 369-377.	2.5	6
129	Afatinib monotherapy in patients with metastatic squamous cell carcinoma of the lung progressing after erlotinib/ gefitinib (E/G) and chemotherapy: Interim subset analysis from a phase III trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7558-7558.	1.6	6
130	Galaxy-2 trial (NCT01798485): A randomized phase 3 study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced lung adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS8118-TPS8118.	1.6	6
131	Biosimilar trastuzumab-dkst monotherapy versus trastuzumab monotherapy after combination therapy: Final overall survival (OS) from the phase III HERITAGE Trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1021-1021.	1.6	6
132	Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110458.	3.2	6
133	Health-related quality of life in patients with fully resected BRAFV600 mutationâ€“positive melanoma receiving adjuvant vemurafenib. <i>European Journal of Cancer</i> , 2019, 123, 155-161.	2.8	5
134	Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab (R-InO) versus chemotherapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8529-8529.	1.6	5
135	Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: Final results of a phase III trial (901) and efficacy results of a 2nd line tivozanib extension study (902).. <i>Journal of Clinical Oncology</i> , 2015, 33, 4557-4557.	1.6	5
136	An Unusual Complication of Three-Patch Repair of Supravalvar Aortic Stenosis. <i>Annals of Thoracic Surgery</i> , 2014, 98, 1449-1451.	1.3	4
137	Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9125-9125.	1.6	4
138	Randomized phase 2 study of abiraterone acetate (AA) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptorâ€“positive (ER+) metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 519-519.	1.6	4
139	Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin.. <i>Journal of Clinical Oncology</i> , 2016, 34, LBA503-LBA503.	1.6	4
140	Biosimilar trastuzumab-dkst monotherapy versus trastuzumab monotherapy after combination therapy: Toxicity, efficacy, and immunogenicity from the phase 3 Heritage trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 110-110.	1.6	4
141	CONTESSA: A multinational, multicenter, randomized, phase III registration study of tesetaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (LA/MBC) who have previously received a taxane.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS1107-TPS1107.	1.6	4
142	The Phantom for Studying Foreign Bodiesâ€™™ Echo-Signs. <i>International Journal of Biomedicine</i> , 2020, 10, 124-128.	0.2	4
143	Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 â‰¥ 50%: Results from EMPOWER-Lung 1 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9078-9078.	1.6	3
144	Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial. <i>Breast</i> , 2021, 58, 18-26.	2.2	3

#	ARTICLE	IF	CITATIONS
145	A Phase II, Randomized, Multi-Centre, Open-Label, Active-Controlled, Dose-Finding Trial of F-627 (benefilgrastim) in Women with Breast Cancer Receiving Myelotoxic Chemotherapy. <i>Blood</i> , 2014, 124, 1584-1584.	1.4	3
146	Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib + paclitaxel vs trastuzumab + paclitaxel as first-line treatment for HER2+ metastatic breast cancer (NEfERTT).. <i>Journal of Clinical Oncology</i> , 2015, 33, 610-610.	1.6	3
147	Evaluation of survival by ADCC status: Subgroup analysis of SB3 (Trastuzumab Biosimilar) and reference trastuzumab in patients with HER2-positive early breast cancer at three-year follow-up.. <i>Journal of Clinical Oncology</i> , 2019, 37, 580-580.	1.6	3
148	Outcomes of Patients With Sickle Cell Disease and Trait After Congenital Heart Disease Surgery. <i>Annals of Thoracic Surgery</i> , 2023, 115, 1494-1502.	1.3	3
149	Randomized, controlled, multicenter, multinational phase 2 study of docetaxel (DCT) or AXL1717 treatment in patients with squamous cell carcinoma (SCC) or adenocarcinoma (AC) of non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8091-8091.	1.6	2
150	Antiangiogenic-specific adverse events (AEs) in patients with non-small cell lung cancer (NSCLC) treated with nintedanib (N) and docetaxel (D).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8100-8100.	1.6	2
151	ARIEL4: An international, multicenter randomized phase 3 study of the PARP inhibitor rucaparib vs chemotherapy in germline or somatic BRCA1- or BRCA2-mutated, relapsed, high-grade ovarian carcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS5603-TPS5603.	1.6	2
152	Hematologic adverse events following palbociclib (PAL) dose reduction in patients (pts) with hormone receptor+ (HR+)/human epidermal growth factor receptor 2- (HER2-) advanced breast cancer (ABC): Pooled analysis from randomized phase 2 and 3 studies.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1060-1060.	1.6	2
153	Milestones over the development of SB3, a trastuzumab biosimilar. <i>Future Oncology</i> , 2018, 14, 2795-2803.	2.4	1
154	Abstract OT1-08-09: CONTESSA: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane. , 2020, , .		1
155	A randomized phase II study of axitinib in combination with pemetrexed/cisplatin (pem/cis) as first-line therapy for nonsquamous non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 7551-7551.	1.6	1
156	Efficacy and safety of lipegfilgrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy.. <i>Journal of Clinical Oncology</i> , 2012, 30, e19587-e19587.	1.6	1
157	Vinflunine plus capecitabine for advanced breast cancer previously treated with or resistant to anthracycline and resistant to taxane: A phase III study versus capecitabine.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1013-1013.	1.6	1
158	The effect of palbociclib (P) in combination with letrozole (L) on bone metastases in women with ER+/HER2- metastatic breast cancer (MBC): Subanalysis from a randomized phase II study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 572-572.	1.6	1
159	Results of bevacizumab biosimilar compared with RMP for the treatment of metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14065-e14065.	1.6	1
160	A comparative clinical study of PF-06439535, a candidate bevacizumab biosimilar, and reference bevacizumab, in patients with advanced non-squamous non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 109-109.	1.6	1
161	Contessa: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS1106-TPS1106.	1.6	1
162	Additional one-year follow-up study to evaluate safety and survival in patients who have completed neoadjuvant-adjuvant treatment with SB3 (trastuzumab biosimilar) or reference trastuzumab in HER2-positive early or locally advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, e12631-e12631.	1.6	1

#	ARTICLE	IF	CITATIONS
163	A Phase III, Randomized, Multi-Center, Open-Label, Fixed Dose, Neulasta Active-Controlled Clinical Trial of F-627, a Novel G-CSF, in Women with Breast Cancer Receiving Myelotoxic Chemotherapy. <i>Blood</i> , 2021, 138, 4290-4290.	1.4	1
164	Application of new methodology to allow comparison of duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial. <i>Breast</i> , 2011, 20, S45.	2.2	0
165	Usefulness of CT for diagnosis of breast malignancy metastasis variants to the vertebrae. <i>Przegląd Menopauzalny</i> , 2012, 6, 441-444.	1.3	0
166	PO120 FACTORS AFFECTING CHANGES IN IMMUNOHISTOCHEMISTRY PHENOTYPE OF BREAST CANCER. <i>Breast</i> , 2013, 22, S60.	2.2	0
167	O11-5 Durvalumab(D) + tremelimumab(T) + platinum-etoposide(EP) in 1L ES-SCLC: Characterization of long-term benefit in CASPIAN. <i>Annals of Oncology</i> , 2021, 32, S289.	1.2	0
168	Evaluation Of Electrocardiogram Parameters In Patients With Breast and Lung Cancer Treated With Chemotherapy and Lipegfilgrastim Or Pegfilgrastim. <i>Blood</i> , 2013, 122, 4856-4856.	1.4	0
169	Final analysis: Randomized, blinded, placebo-controlled phase II trial of sorafenib with and without mapatumumab in patients with advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4029-4029.	1.6	0
170	Evaluation of biomarker association with efficacy for abiraterone acetate (AA) plus prednisone (P) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor-positive (ER+) metastatic breast cancer (mBCa) progressing after a nonsteroidal aromatase inhibitor (NSAI).. <i>Journal of Clinical Oncology</i> , 2014, 32, 520-520.	1.6	0
171	Abstract S5-07: A randomized, open-label, multicenter, phase 3 study of epoetin alfa (EPO) plus standard supportive care versus standard supportive care in anemic patients with metastatic breast cancer (MBC) receiving standard chemotherapy. , 2015, , .		0
172	Efficacy and safety of adding the retinoid tamibarotene or placebo to paclitaxel/carboplatin for advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e19034-e19034.	1.6	0
173	Elsiglutide in the primary prevention of chemotherapy (CT)-induced diarrhea in patients with colorectal cancer (CRC) receiving 5-fluorouracil (5-FU)-based CT: A multinational, randomized, double-blind, placebo-controlled study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10101-10101.	1.6	0
174	Plinabulin (Plin), a small molecule with anti-cancer activity and a novel mechanism of action (MoA) in docetaxel (Tax)-induced neutropenia: Phase (I†) 2 results from a head-to-head comparison with Pegfilgrastim (Peg).. <i>Journal of Clinical Oncology</i> , 2018, 36, 2528-2528.	1.6	0
175	Abstract OT1-08-07: CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane. , 2020, , .		0
176	Abstract OT1-08-08: CONTESSA TRIO: A multinational, multicenter, phase 2 study of tesetaxel plus 3 different PD-(L)1 inhibitors in patients with metastatic triple-negative breast cancer (TNBC) and tesetaxel monotherapy in elderly patients with HER2- metastatic breast cancer (MBC). , 2020, , .		0
177	Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. <i>Cancers</i> , 2022, 14, 1168.	3.7	0